Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,otherLiab,goodWill,treasuryStock,otherAssets,cash,totalCurrentLiabilities,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,netReceivables,inventory,accountsPayable,longTermInvestments,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,changeToInventory,changeToAccountReceivables,changeToNetincome,capitalExpenditures,investments,issuanceOfStock,otherCashflowsFromInvestingActivities,otherCashflowsFromFinancingActivities,WC,language,region,quoteType,triggerable,quoteSourceName,market,currency,twoHundredDayAverageChangePercent,exchangeDataDelayedBy,marketState,exchange,esgPopulated,tradeable,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,priceHint,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,epsTrailingTwelveMonths,gmtOffSetMilliseconds,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,marketCap,shortName,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,Shares Short 4,Short Ratio 4,Short % of Float 4,Short % of Shares Outstanding 4,Shares Short (prior month ) 4,Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,compensationAsOfEpochDate,country,website,maxAge,address1,fax,industry
t0,HPHA.DE,-2352083.0,31066400,4863575,,-6320547,,-6320547,805551,-705736,-6374862,-6374862,,-36909,,,,0,370284,6745146,1076020,54315,,-6320547,-6320547,2869377.0,221896978.0,10912729.0,6628460.0,5506004.0,17541189.0,31061872.0,284509.0,-251874223.0,-1.0,6111166.0,5543833.0,44899.0,2914651.0,10833485.0,5543833.0,3307831.0,5207916.0,1433906.0,574850.0,2603961.0,,11855.0,-433649.0,4974961.0,4974961.0,-454482.0,-2067581.0,-7747.0,-6601148.0,188783.0,-345030.0,206412.0,111861.0,-389005.0,,,,,-5625569.0,en-US,US,EQUITY,False,Delayed Quote,de_market,EUR,-0.09218143,0,REGULAR,GER,False,False,6.66,1630568163,-0.09000015,6.66,6.69,6.52,8375,31.267605,15,Europe/Berlin,CEST,2,-1.3333356,6.52 - 6.69,6.75,6.6,6.68,finmb_131424,XETRA,Heidelberg Pharma AG,EUR,9326,2519,3.57,1.1553398,3.09 - 9.7,-3.04,-0.31340206,3.09,9.7,1625725800,1625725800,1625725800,-0.656,7200000,0.213,6.9514284,-0.29142857,-0.041923553,7.3362675,-0.6762676,206902224,HEIDELBERG PHARMA AG O.N.,-0.7,,,9.7,3.09,6.95,7.34,9.33k,2.52k,31.07M,,8.35M,72.94%,0.07%,,,,,,,,,,,0.00%,,,,,"Nov 30, 2020","Feb 28, 2021",-266.86%,-273.59%,-70.51%,-217.18%,7.54M,0.25,-75.30%,3.07M,-19.94M,-20.12M,-0.66,,2.91M,0.09,178.04k,2.69,0.48,0.21,-19.86M,-9.09M,Value,68526,Healthcare,82,"Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, other European countries, the United States, and internationally. It is developing HDP-101 for the treatment of multiple myeloma; HDP-102 for the treatment of non-Hodgkin lymphoma; HDP-103, an ATAC candidate to treat prostate cancer; and CDXX-ATACs, a candidate for the treatment of solid/hematological tumors. The company is also developing MGTA-ATACs for HSCs, conditioning programs for blood cancers, and genetic diseases; TAK-ATACs for oncology treatment; and EMR-ATAC for the treatment of solid tumors. In addition, it provides preclinical research services in the fields of cancer, and inflammatory and autoimmune diseases. The company was formerly known as Wilex AG and changed its name to Heidelberg Pharma AG in October 2017. Heidelberg Pharma AG was founded in 1997 and is based in Ladenburg, Germany.",Ladenburg,49 6203 1009 0,1609372800,Germany,http://heidelberg-pharma.com,86400,Gregor-Mendel-Strasse 22,49 6203 1009 19,Biotechnology
t-1,HPHA.DE,3949576.0,31066400,4739248,,-5901025,,-5901025,1509486,36640,-5837038,-5837038,-375056.0,-6688,,,,0,1179107,7016145,1142467,-63987,,-5901025,-5901025,2818316.0,221896978.0,6729734.0,12879058.0,252111.0,19608792.0,31061872.0,,-245553676.0,,6111166.0,5473884.0,44900.0,4982232.0,6627704.0,5473884.0,3113628.0,7520782.0,1509782.0,229820.0,2811832.0,,-144254.0,-316775.0,-20548.0,7424.0,-41364.0,-4243295.0,823.0,-3934767.0,324307.0,79334.0,1425708.0,311527.0,-425863.0,-58155.0,27972.0,-1.0,,893078.0,en-US,US,EQUITY,False,Delayed Quote,de_market,EUR,-0.09218143,0,REGULAR,GER,False,False,6.66,1630568163,-0.09000015,6.66,6.69,6.52,8375,31.267605,15,Europe/Berlin,CEST,2,-1.3333356,6.52 - 6.69,6.75,6.6,6.68,finmb_131424,XETRA,Heidelberg Pharma AG,EUR,9326,2519,3.57,1.1553398,3.09 - 9.7,-3.04,-0.31340206,3.09,9.7,1625725800,1625725800,1625725800,-0.656,7200000,0.213,6.9514284,-0.29142857,-0.041923553,7.3362675,-0.6762676,206902224,HEIDELBERG PHARMA AG O.N.,-0.7,,,9.7,3.09,6.95,7.34,9.33k,2.52k,31.07M,,8.35M,72.94%,0.07%,,,,,,,,,,,0.00%,,,,,"Nov 30, 2020","Feb 28, 2021",-266.86%,-273.59%,-70.51%,-217.18%,7.54M,0.25,-75.30%,3.07M,-19.94M,-20.12M,-0.66,,2.91M,0.09,178.04k,2.69,0.48,0.21,-19.86M,-9.09M,Value,68526,Healthcare,82,"Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, other European countries, the United States, and internationally. It is developing HDP-101 for the treatment of multiple myeloma; HDP-102 for the treatment of non-Hodgkin lymphoma; HDP-103, an ATAC candidate to treat prostate cancer; and CDXX-ATACs, a candidate for the treatment of solid/hematological tumors. The company is also developing MGTA-ATACs for HSCs, conditioning programs for blood cancers, and genetic diseases; TAK-ATACs for oncology treatment; and EMR-ATAC for the treatment of solid tumors. In addition, it provides preclinical research services in the fields of cancer, and inflammatory and autoimmune diseases. The company was formerly known as Wilex AG and changed its name to Heidelberg Pharma AG in October 2017. Heidelberg Pharma AG was founded in 1997 and is based in Ladenburg, Germany.",Ladenburg,49 6203 1009 0,1609372800,Germany,http://heidelberg-pharma.com,86400,Gregor-Mendel-Strasse 22,49 6203 1009 19,Biotechnology
t-2,HPHA.DE,9686687.0,31066400,4843189,,-3045270,,-3045270,625082,2542015,-3195312,-3195312,269056.0,-859,,,,0,4368279,7563591,1826264,150042,,-3045270,-3045270,2806567.0,221883806.0,6793965.0,18604420.0,1129884.0,25398385.0,31047072.0,120347.0,-239652652.0,24908.0,6111166.0,5326194.0,44899.0,9225527.0,6643453.0,5326194.0,3313814.0,13109340.0,3454312.0,309154.0,2053406.0,12599.0,-498725.0,-239601.0,-24804.0,-5529.0,-506664.0,-5903516.0,1081.0,-5659467.0,138487.0,274136.0,-2118392.0,96961.0,-214193.0,-58155.0,31185.0,-1.0,-11910.0,6465887.0,en-US,US,EQUITY,False,Delayed Quote,de_market,EUR,-0.09218143,0,REGULAR,GER,False,False,6.66,1630568163,-0.09000015,6.66,6.69,6.52,8375,31.267605,15,Europe/Berlin,CEST,2,-1.3333356,6.52 - 6.69,6.75,6.6,6.68,finmb_131424,XETRA,Heidelberg Pharma AG,EUR,9326,2519,3.57,1.1553398,3.09 - 9.7,-3.04,-0.31340206,3.09,9.7,1625725800,1625725800,1625725800,-0.656,7200000,0.213,6.9514284,-0.29142857,-0.041923553,7.3362675,-0.6762676,206902224,HEIDELBERG PHARMA AG O.N.,-0.7,,,9.7,3.09,6.95,7.34,9.33k,2.52k,31.07M,,8.35M,72.94%,0.07%,,,,,,,,,,,0.00%,,,,,"Nov 30, 2020","Feb 28, 2021",-266.86%,-273.59%,-70.51%,-217.18%,7.54M,0.25,-75.30%,3.07M,-19.94M,-20.12M,-0.66,,2.91M,0.09,178.04k,2.69,0.48,0.21,-19.86M,-9.09M,Value,68526,Healthcare,82,"Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, other European countries, the United States, and internationally. It is developing HDP-101 for the treatment of multiple myeloma; HDP-102 for the treatment of non-Hodgkin lymphoma; HDP-103, an ATAC candidate to treat prostate cancer; and CDXX-ATACs, a candidate for the treatment of solid/hematological tumors. The company is also developing MGTA-ATACs for HSCs, conditioning programs for blood cancers, and genetic diseases; TAK-ATACs for oncology treatment; and EMR-ATAC for the treatment of solid tumors. In addition, it provides preclinical research services in the fields of cancer, and inflammatory and autoimmune diseases. The company was formerly known as Wilex AG and changed its name to Heidelberg Pharma AG in October 2017. Heidelberg Pharma AG was founded in 1997 and is based in Ladenburg, Germany.",Ladenburg,49 6203 1009 0,1609372800,Germany,http://heidelberg-pharma.com,86400,Gregor-Mendel-Strasse 22,49 6203 1009 19,Biotechnology
t-3,HPHA.DE,12636350.0,31066400,4823321,,-4852204,,-4852204,892768,497389,-5218700,-5218700,269056.0,-2590,,,,0,1621419,6840119,1124030,366496,,-4852204,-4852204,2782803.0,221881031.0,7544745.0,21530319.0,1837092.0,29075064.0,31030572.0,,-236607382.0,54805.0,6111166.0,5226098.0,44900.0,15129043.0,7351261.0,5226098.0,3150726.0,16972870.0,1126284.0,583290.0,1815025.0,12599.0,227516.0,-401164.0,-24754.0,14312778.0,393187.0,10225982.0,-23575.0,-3662057.0,135944.0,259932.0,5792.0,167776.0,-398866.0,-58155.0,14386901.0,-1.0,-49369.0,9621609.0,en-US,US,EQUITY,False,Delayed Quote,de_market,EUR,-0.09218143,0,REGULAR,GER,False,False,6.66,1630568163,-0.09000015,6.66,6.69,6.52,8375,31.267605,15,Europe/Berlin,CEST,2,-1.3333356,6.52 - 6.69,6.75,6.6,6.68,finmb_131424,XETRA,Heidelberg Pharma AG,EUR,9326,2519,3.57,1.1553398,3.09 - 9.7,-3.04,-0.31340206,3.09,9.7,1625725800,1625725800,1625725800,-0.656,7200000,0.213,6.9514284,-0.29142857,-0.041923553,7.3362675,-0.6762676,206902224,HEIDELBERG PHARMA AG O.N.,-0.7,,,9.7,3.09,6.95,7.34,9.33k,2.52k,31.07M,,8.35M,72.94%,0.07%,,,,,,,,,,,0.00%,,,,,"Nov 30, 2020","Feb 28, 2021",-266.86%,-273.59%,-70.51%,-217.18%,7.54M,0.25,-75.30%,3.07M,-19.94M,-20.12M,-0.66,,2.91M,0.09,178.04k,2.69,0.48,0.21,-19.86M,-9.09M,Value,68526,Healthcare,82,"Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, other European countries, the United States, and internationally. It is developing HDP-101 for the treatment of multiple myeloma; HDP-102 for the treatment of non-Hodgkin lymphoma; HDP-103, an ATAC candidate to treat prostate cancer; and CDXX-ATACs, a candidate for the treatment of solid/hematological tumors. The company is also developing MGTA-ATACs for HSCs, conditioning programs for blood cancers, and genetic diseases; TAK-ATACs for oncology treatment; and EMR-ATAC for the treatment of solid tumors. In addition, it provides preclinical research services in the fields of cancer, and inflammatory and autoimmune diseases. The company was formerly known as Wilex AG and changed its name to Heidelberg Pharma AG in October 2017. Heidelberg Pharma AG was founded in 1997 and is based in Ladenburg, Germany.",Ladenburg,49 6203 1009 0,1609372800,Germany,http://heidelberg-pharma.com,86400,Gregor-Mendel-Strasse 22,49 6203 1009 19,Biotechnology
